Bellevue Group »

Nuvalent Inc-a shares owned by Bellevue Group

Quarter-by-quarter ownership of Nuvalent Inc-a (NUVL) shares owned by Bellevue Group from 13F filings

Historical chart of Bellevue Group investment in Nuvalent Inc-a

Tip: Access up to 7 years of quarterly data

All positions including Nuvalent Inc-a held by Bellevue Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Nuvalent Inc-a by Bellevue Group

Quarter filed Position value Share count Share price at filing
2025-12-31 $104M 1.0M 100.59

More positions owned by Bellevue Group

Revolution Medicines (RVMD)
Argenx Se Sponsored Adr (ARGX)
Ionis Pharmaceuticals (IONS)
Vertex Pharmaceuticals Incorporated (VRTX)
Neurocrine Biosciences (NBIX)
Avidity Biosciences Ord (RNA)
Intuitive Surgical Com New (ISRG)
Scholar Rock Hldg Corp (SRRK)
Alnylam Pharmaceuticals (ALNY)
Abbott Laboratories (ABT)
Amicus Therapeutics (FOLD)
Boston Scientific Corporation (BSX)
Miragen Therapeutics (VRDN)
Stryker Corporation (SYK)
Nuvalent Inc-a (NUVL)

View all positions for Bellevue Group

Top funds holding Nuvalent Inc-a

Deerfield Management Company
FMR
Paradigm Biocapital Advisors
Vanguard Group
BlackRock
Wellington Management Company
Henderson Group
State Street Corporation
Jpmorgan Chase & Co
Perceptive Advisors
Commodore Capital
T. Rowe Price Investment Management
RA Capital Management
Geode Capital Management
Vestal Point Capital

View all funds holding Nuvalent Inc-a